問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Taipei Medical University Hospital (在職)

Division of Thoracic Medicine

Division of General Internal Medicine

更新時間：2023-09-19

徐上富Hsu, Shang-Fu
  • Co-Principal Investigator
  • Clinical Trial Experience (year) 7 years 9 個月

Recruiting Trial

80Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

徐上富

List

89Cases

2020-04-01 - 2022-05-31

Phase II

Completed
Randomized, double-blind, parallel group, Phase 2b dose-finding, efficacy and safety study of 12-week twice daily oral administration of BAY 1817080 compared to placebo in the treatment of refractory and/or unexplained chronic cough (RUCC)

  • Condition/Disease

    refractory and/or unexplained chronic cough (RUCC)

  • Test Drug

    BAY 1817080

Participate Sites
5Sites

Recruiting5Sites

2025-10-01 - 2028-12-31

Phase II/III

Active
IZABRIGHT-Lung01: A Randomized, Open-label, Phase 2/3 Study of Izalontamab Brengitecan (BMS-986507) versus Platinum-based Chemotherapy in Patients with EGFR-mutated Non-small Cell Lung Cancer and Disease Progression on EGFR Tyrosine Kinase Inhibitor Therapy

  • Condition/Disease

    EGFR-mutated Non-small Cell Lung Cancer

  • Test Drug

    powder

Participate Sites
6Sites

Recruiting6Sites

2025-08-01 - 2032-03-02

Phase II

Active
A Randomized Phase 2/3 Study of BMS-986504 in Combination with Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants with Homozygous MTAP Deletion

  • Condition/Disease

    Non-small Cell Lung Cancer

  • Test Drug

    tablet

Participate Sites
5Sites

Recruiting5Sites

2023-04-01 - 2026-12-31

Phase I

Active

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Not yet recruiting5Sites

Recruiting2Sites

2022-11-15 - 2034-07-12

Others

xxxxxx

  • Condition/Disease

    xxxxxx

  • Test Drug

    AlectinibEntrectinibEntrectinibPralsetinibDurvalumab

Participate Sites
8Sites

Recruiting8Sites

2023-07-01 - 2030-06-30

Phase II/III

A Randomized, Double-Blind Phase 2/3 Study of Fianlimab (Anti-LAG-3 Antibody) in Combination With Cemiplimab (Anti-PD-1 Antibody) Versus Cemiplimab Monotherapy in First-Line Treatment of Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) With Tumors Expressing PD-L1 ≥50%

  • Condition/Disease

    Advanced Non-Small Cell Lung Cancer

  • Test Drug

    REGN3767 (Fianlimab) REGN2810 (Cemiplimab)

Participate Sites
8Sites

Recruiting8Sites

2024-02-06 - 2029-08-30

Phase II

Active
A PHASE 2 PERI-OPERATIVE TRIAL OF FIANLIMAB AND CEMIPLIMAB IN COMBINATION WITH CHEMOTHERAPY VERSUS CEMIPLIMAB IN COMBINATION WITH CHEMOTHERAPY IN PATIENTS WITH RESECTABLE EARLY STAGE (STAGE II TO IIIB [N2]) NSCLC

  • Condition/Disease

    NSCLC

  • Test Drug

    REGN3767 (Fianlimab) REGN2810 (Cemiplimab)

Participate Sites
9Sites

Not yet recruiting8Sites

Recruiting1Sites

2020-11-30 - 2023-12-31

Phase IV

andomized, double blind, placebo controlled study to evaluate the effect of dupilumab on airway inflammation through assessments of lung function, mucus plugging and other lung imaging parameters in patients with asthma

  • Condition/Disease

    asthma

  • Test Drug

    Dupilumab

Participate Sites
4Sites

Recruiting3Sites

Terminated1Sites

2022-05-01 - 2026-03-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting6Sites

2023-07-07 - 2026-07-31

Phase I

Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC), Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors, Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Budigalimab

  • Condition/Disease

    Non-Small Cell Lung Cancer、 Head and Neck Squamous Cell Carcinoma

  • Test Drug

    ABBV-514ABBV-181 (Budigalimab)

Participate Sites
5Sites

Recruiting5Sites

1 5 6 7 8 9
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB